Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 59 (10), 6140-50

Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium Tuberculosis in New York City


Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium Tuberculosis in New York City

Dawn Verdugo et al. Antimicrob Agents Chemother.


Pyrazinamide (PZA) has important sterilizing activity in tuberculosis (TB) chemotherapy. We describe trends, risk factors, and molecular epidemiology associated with PZA-resistant (PZA(r)) Mycobacterium tuberculosis in New York City (NYC). From 2001 to 2008, all incident culture-positive TB cases reported by the NYC Department of Health and Mental Hygiene (DOHMH) were genotyped by IS6110-based restriction fragment length polymorphism and spoligotype. Multidrug-resistant (MDR) isolates underwent DNA sequencing of resistance-determining regions of pncA, rpoB, katG, and fabG1. Demographic and clinical information were extracted from the NYC DOHMH TB registry. During this period, PZA(r) doubled (1.6% to 3.6%) overall, accounting for 44% (70/159) of the MDR population and 1.4% (75/5511) of the non-MDR population. Molecular genotyping revealed strong microbial phylogenetic associations with PZA(r). Clustered isolates and those from acid-fast bacillus (AFB) smear-positive cases had 2.7 (95% confidence interval [CI] = 1.71 to 4.36) and 2.0 (95% CI = 1.19 to 3.43) times higher odds of being PZA(r), respectively, indicating a strong likelihood of recent transmission. Among the MDR population, PZA(r) was acquired somewhat more frequently via primary transmission than by independent pathways. Our molecular analysis also revealed that several historic M. tuberculosis strains responsible for MDR TB outbreaks in the early 1990s were continuing to circulate in NYC. We conclude that the increasing incidence of PZA(r), with clear microbial risk factors, underscores the importance of routine PZA drug susceptibility testing and M. tuberculosis genotyping for the identification, control, and prevention of increasingly resistant organisms.


Study schema. MDR, resistant to at least isoniazid and rifampin; PZAR, PZA resistant; PZAS, PZA susceptible; mono-PZAR, resistant only to PZA and no other drug; MDR-PZAR, resistant to at least isoniazid, rifampin, and PZA; poly-PZAR, resistant to PZA and at least one other drug, excluding MDR-PZAR.
Distribution of PZAr, mono-PZAr, and MDR-PZAr TB in NYC from 2001 to 2008.

Similar articles

See all similar articles

Cited by 5 articles

Publication types